Stada Group
Stephan Eder has held various key positions in the pharmaceutical industry, including being the CEO of Hexal AG and Country Head for Germany at Sandoz. Stephan has also served as the Director of Corporate Strategy at Novartis International AG. In addition, Eder has experience as an Engagement Manager at McKinsey & Company and as a Research and Teaching Assistant at the University of St. Gallen - HSG. Eder is a co-founder and CFO of a biotech startup, 55pharma Drug Discovery & Development AG. Stephan holds a Dr. oec. degree in Business Administration and Management from the University of St.Gallen.
Stada Group
14 followers
Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products. The Branded Products segment focuses on multisource products accessible without active ingredient research, notably anti-enzymatic food intolerance drugs that are marketed by the subsidiary SCIOTEC Diagnostics Technologies. The Company's generic drugs are marketed by the Group subsidiary, STADApharm GmbH. Non-core activities of the Company encompass Commercial Business segment, which includes activities with primarily trading character such as wholesaling activities. The Company operates STADA Pharmaceuticals Australia Pty Ltd and STADA IT SOLUTIONS DOO as subsidiaries.